Ischemic optic neuropathy

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Ischemic optic neuropathy | |
|---|---|
| Synonyms | ION |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Sudden vision loss, visual field defect |
| Complications | Permanent vision loss |
| Onset | Sudden |
| Duration | Variable |
| Types | Anterior ischemic optic neuropathy, Posterior ischemic optic neuropathy |
| Causes | Atherosclerosis, giant cell arteritis, hypertension, diabetes mellitus |
| Risks | Age, smoking, hypertension, diabetes |
| Diagnosis | Clinical examination, visual field test, fluorescein angiography |
| Differential diagnosis | Optic neuritis, retinal detachment, central retinal artery occlusion |
| Prevention | Control of risk factors |
| Treatment | Corticosteroids, aspirin, management of underlying conditions |
| Medication | N/A |
| Prognosis | Variable, often poor for vision recovery |
| Frequency | Common in older adults |
| Deaths | N/A |
Ischemic optic neuropathy (ION) is a condition characterized by damage to the optic nerve due to insufficient blood supply. It is a significant cause of sudden vision loss in adults, particularly affecting those over the age of 50. ION is classified into two main types: anterior ischemic optic neuropathy (AION) and posterior ischemic optic neuropathy (PION).
Types[edit]
Anterior Ischemic Optic Neuropathy (AION)[edit]
AION is the most common form of ischemic optic neuropathy and occurs when there is inadequate blood flow to the anterior portion of the optic nerve. It is further divided into two subtypes:
- Non-arteritic AION (NAION): This is the more prevalent form and is associated with risk factors such as hypertension, diabetes mellitus, and hyperlipidemia. It is thought to result from small vessel disease affecting the optic nerve head.
- Arteritic AION (AAION): This form is less common and is primarily caused by giant cell arteritis, an inflammatory condition of the blood vessels. AAION is a medical emergency due to the risk of bilateral vision loss.
Posterior Ischemic Optic Neuropathy (PION)[edit]
PION is less common than AION and involves ischemia of the posterior part of the optic nerve. It can occur in association with systemic conditions such as severe blood loss, hypotension, or after surgical procedures.
Symptoms[edit]
The primary symptom of ischemic optic neuropathy is sudden, painless vision loss in one eye. Patients may also experience visual field defects, such as altitudinal field loss, where the upper or lower half of the visual field is affected.
Diagnosis[edit]
Diagnosis of ION is based on clinical examination and history. Key diagnostic tools include:
- Ophthalmoscopy: To examine the optic disc for signs of swelling or pallor.
- Visual field test: To assess the extent and pattern of vision loss.
- Fluorescein angiography: To evaluate blood flow to the optic nerve.
- Blood tests: To check for underlying conditions such as giant cell arteritis.
Treatment[edit]
Treatment of ischemic optic neuropathy depends on the underlying cause. For NAION, management focuses on controlling risk factors like hypertension and diabetes. In cases of AAION, immediate treatment with high-dose corticosteroids is crucial to prevent further vision loss.
Prognosis[edit]
The prognosis for vision recovery in ischemic optic neuropathy varies. In NAION, some patients may experience partial improvement, but significant recovery is uncommon. In AAION, prompt treatment can prevent further vision loss, but recovery of lost vision is rare.
Prevention[edit]
Preventive measures for ischemic optic neuropathy include managing systemic risk factors such as blood pressure, blood sugar, and cholesterol levels. Regular eye examinations are also important for early detection and management of potential risk factors.
See also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
